Biological Products, Except Diagnostic Substances (Biotech) - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the Biological industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

Biological Products, Except Diagnostic Substances (Biotech) - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - Biological Products, Except Diagnostic Substances (Biotech)
Corporate Insider Buy Sell Ratio (Insider Count) - Biological Products, Except Diagnostic Substances (Biotech)
Biological Products, Except Diagnostic Substances (Biotech) - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2026-03-31 KYMR / Kymera Therapeutics, Inc. 4 Ridloff Elena S - Sale D 85.3701 -7,400
2026-03-31 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G S - Sale D 85.3792 -7,600
2026-03-31 CRIS / Curis, Inc. 4 KAITIN KENNETH I P - Purchase D 0.5487 10,000
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Sayad Pierre Sargis M - Exercise D 18,456
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Evans Terry L M - Exercise D 18,456
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Hackman Jeffrey S. M - Exercise D 16,695
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Andrade Robert M - Exercise D 2,213
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Hackman Jeffrey S. M - Exercise D 1,159
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Sayad Pierre Sargis M - Exercise D 171
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Evans Terry L M - Exercise D 171
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Andrade Robert M - Exercise D 14,724
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Cioffi Christiana Marie M - Exercise D 158
2026-03-31 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 7.27 14,722
2026-03-31 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G M - Exercise D 29.64 7,600
2026-03-31 KYMR / Kymera Therapeutics, Inc. 4 Ridloff Elena M - Exercise D 14.18 7,400
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Cioffi Christiana Marie M - Exercise D 17,106
2026-03-31 BEAM / Beam Therapeutics Inc. 4 Evans John M. M - Exercise D 0.67 25,000
2026-03-31 SRZN / Surrozen, Inc. 4 Li Yang G - Gift D -1,666
2026-03-31 IBRX / ImmunityBio, Inc. 4 SOON-SHIONG PATRICK C - Conversion I 5.427 4,606,596
2026-03-31 CVM / CEL-SCI Corporation 4 TALOR EYAL A - Award D 3.21 747
2026-03-31 BEAM / Beam Therapeutics Inc. 4 Evans John M. A - Award D 90,000
2026-03-31 BEAM / Beam Therapeutics Inc. 4 Emany Sravan Kumar A - Award D 31,750
2026-03-31 CVM / CEL-SCI Corporation 4 PRICHEP PATRICIA B A - Award D 3.21 1,336
2026-03-31 CVM / CEL-SCI Corporation 4 KERSTEN GEERT R A - Award D 3.21 1,682
2026-03-31 BEAM / Beam Therapeutics Inc. 4 Simon Amy A - Award D 31,750
2026-03-31 BEAM / Beam Therapeutics Inc. 4 Bellon Christine A - Award D 20,000
2026-03-31 BEAM / Beam Therapeutics Inc. 4 Ciaramella Giuseppe A - Award D 40,000
2026-03-31 BEAM / Beam Therapeutics Inc. 4 Cavanagh Bethany J A - Award D 20,000
2026-03-31 FENC / Fennec Pharmaceuticals Inc. 4 Raykov Rosty A - Award D 5,208
2026-03-30 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE S - Sale D 12.63 -19,060
2026-03-30 BEAM / Beam Therapeutics Inc. 4 Evans John M. S - Sale D 22.3692 -25,000
2026-03-30 BEAM / Beam Therapeutics Inc. 4 Evans John M. M - Exercise D 0.67 25,000
2026-03-30 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 7.27 14,722
2026-03-28 FENC / Fennec Pharmaceuticals Inc. 4 Cioffi Christiana Marie M - Exercise D 1,901
2026-03-28 FENC / Fennec Pharmaceuticals Inc. 4 Sayad Pierre Sargis M - Exercise D 2,052
2026-03-28 FENC / Fennec Pharmaceuticals Inc. 4 Evans Terry L M - Exercise D 2,052
2026-03-28 FENC / Fennec Pharmaceuticals Inc. 4 Hackman Jeffrey S. M - Exercise D 13,943
2026-03-28 FENC / Fennec Pharmaceuticals Inc. 4 Andrade Robert M - Exercise D 12,270
2026-03-28 VXRT / Vaxart, Inc. 4 Tucker Sean F - Taxes D 0.65 -3,924
2026-03-28 VXRT / Vaxart, Inc. 4 Cummings James F. F - Taxes D 0.65 -3,292
2026-03-27 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE S - Sale D 12.49 -2,738
2026-03-27 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE S - Sale D 13.48 -16,322
2026-03-27 GILD / Gilead Sciences, Inc. 4 O'Day Daniel Patrick S - Sale D 136.8162 -10,000
2026-03-27 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 7.27 14,722
2026-03-26 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE S - Sale D 14.12 -19,060
2026-03-26 CGEN / Compugen Ltd. 4 Levine Zurit S - Sale D 2.0368 -11,875
2026-03-26 CGEN / Compugen Ltd. 4 Levine Zurit M - Exercise D 0.8292 11,875
2026-03-26 FENC / Fennec Pharmaceuticals Inc. 4 Andrade Robert M - Exercise D 5.10 13,072
2026-03-26 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 7.27 14,722
2026-03-26 FENC / Fennec Pharmaceuticals Inc. 4 Cioffi Christiana Marie M - Exercise D 4.23 4,700
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)